Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from China Medical System Holdings ( (HK:0867) ).
China Medical System Holdings has called its annual general meeting for 23 April 2026 in Hong Kong, where shareholders will review and adopt the audited 2025 financial statements and related board and auditor reports. The board will also seek approval of a final dividend of RMB0.1366 per share for 2025, the re-election of two directors and authorization of their remuneration, as well as the reappointment of Deloitte Touche Tohmatsu as auditor.
Shareholders will be asked to approve a general mandate allowing the board to issue, allot and deal with new shares, including certain derivative securities, up to 20% of the company’s issued share capital, excluding treasury shares. If passed, the mandate would give the board greater flexibility to raise capital or pursue strategic transactions, reinforcing the group’s financial maneuverability while potentially diluting existing holdings if fully utilized.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a pharmaceutical group incorporated in the Cayman Islands and listed in Hong Kong and Singapore. The company operates through subsidiaries to market and distribute prescription drugs and related medical products, focusing on the Chinese healthcare market and broader regional demand for specialty therapeutics.
Average Trading Volume: 3,997,328
Technical Sentiment Signal: Buy
Current Market Cap: HK$32.64B
For a thorough assessment of 0867 stock, go to TipRanks’ Stock Analysis page.